
Michael J. Zelefsky, MD
Radiation Oncologist
Titles
Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service; Steven A. Greenberg Chair in Prostate Cancer Research
Clinical Expertise
Prostate Cancer (Brachytherapy, Intensity-Modulated Radiation Therapy [IMRT], Image-Guided Radiation Therapy [IGRT])
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Zelefsky accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 212-639-6802 Office Phone
- Speaks English

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Albert Einstein College of Medicine
Residencies
Radiation Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
Radiation Oncology
I am a board-certified radiation oncologist and co-leader of Memorial Sloan Kettering’s Genitourinary Disease Management Team — a multidisciplinary group of physicians who work together to treat patients with urologic malignancies.
Read more
As a recognized expert in the field of radiation therapy, I am Chief of Memorial Sloan Kettering’s Brachytherapy Service. Brachytherapy, which we use to treat many types of cancer, is the delivery of radiation using seeds implanted directly in a tumor.
Our prostate brachytherapy program, which I have helped develop and enhance since joining the staff in 1990, is known for its depth of experience and cutting-edge approach in treating men with prostate cancer. For patients with advanced or aggressive prostate cancer, I have significant expertise using high-dose-rate brachytherapy and temporary brachytherapy, in which patients receive several high-dose treatments either as a boost or as the sole treatment. I also have experience using brachytherapy in patients whose tumor has recurred after external-beam radiation therapy or seed implant, as well as expertise using image-guided stereotactic radiosurgery for areas of metastases (spread) such as bone or lymph nodes.
In addition, I was instrumental in pioneering the use of IMRT (intensity-modulated radiation therapy, which is computer-guided delivery of high doses of radiation directly to the tumor) and IGRT (image-guided radiotherapy, radiation beams targeted precisely to the tumor) for treating men with prostate cancer.
(Learn more about radiation therapy for prostate cancer.)
I am Editor-in-Chief of Brachytherapy, a medical journal that addresses all aspects of this sub-specialty, and Chairman of the National Patterns of Care Study for Genitourinary Cancers. I am a past president of the American Brachytherapy Society.
For my work in this field, I have been honored to receive several awards including the Boyer Award for Excellence in Clinical research, the Outstanding Teaching Award in the Department of Radiation Oncology at Memorial Sloan Kettering, the 2009 Henschke Medal (the highest award of the American Brachytherapy Society for achievements in Brachytherapy), and the 2009 Emanuel Van Descheuren Award for Excellence in Translational Research.
I lecture nationally and internationally about radiation treatments for prostate cancer.
Our prostate brachytherapy program, which I have helped develop and enhance since joining the staff in 1990, is known for its depth of experience and cutting-edge approach in treating men with prostate cancer.
-Dr. Zelefsky
Awards and Honors
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2002-2020)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all Radiation Oncology doctors
See all External Beam Radiotherapy Service, Manhattan doctors
Clinical Trials
- Clinical Trials Investigated by Dr. Zelefsky
- A Phase II Study of Stereotactic Body Radiation Therapy and Radium Dichloride to Treat Prostate Cancer that Has Spread to the Bones
- A Phase II Study of Stereotactic Body Radiation Therapy without Hormonal Therapy in Men with Unfavorable Intermediate-Risk Prostate Cancer
- Clinical Trials Co-Investigated by Dr. Zelefsky
- A Phase II Study of MRI-Guided High-Dose Radiation Therapy in Prostate Cancer
- A Phase II Study of Shorter Course Hormone Therapy and Radiation for High-Risk Prostate Cancer

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Zelefsky’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael J. Zelefsky discloses the following relationships and financial interests:
-
Alpha Tau
Ownership / Equity Interests; Provision of Services -
Boston Scientific
Provision of Services
-
Jay Pharma Inc
Ownership / Equity Interests; Provision of Services -
Mustang Bio
Fiduciary Role/Position; Ownership / Equity Interests
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].